Joint Program in Transfusion Medicine -
Clinical Service

CMCF
The Connell and O'Reilly Families Cell Manipulation Core Facility (CMCF) at Dana-Farber Cancer Institute (DFCI) was created in 1996 to be a facility where normal and neoplastic human cells can be manipulated in preparation for transfusion or injection into human subjects enrolled on clinical trials. The goal of this facility is to assist Dana-Farber/Harvard Cancer Center (DF/HCC) investigators in developing new cell-based therapies for cancer and to support clinical research studies designed to evaluate the toxicity and efficacy of these novel treatments. This facility currently supports a large number of clinical trials that require extensive in vitro cell manipulation. These cellular therapies include processing of hematopoietic stem cells for autologous or allogeneic transplantation, ex vivo generation of modified autologous tumor cells as cancer vaccines and preparation of immune cell populations for adoptive cellular therapy.

The mission of the Cell Manipulation Core Facility is to produce safe and effective cellular components for novel therapeutic clinical research protocols. To fulfill this mission all procedures are performed according to current Good Manufacturing Practices (cGMP) for cell and tissue processing. The policies and procedures established in the facility comply with all current accreditation agency and governmental standards and regulations, ensuring the production of safe, effective components for clinical use. Cellular products processed by the CMCF are provided in the context of clinical research protocols that have been reviewed and approved by the appropriate committees within the DF/HCC.

Additional information on CMCF can be found by clicking here.